全球免疫療法藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計免疫療法藥物市場將從 2025 年的 1,804 億美元成長到 2034 年的 3,455.8 億美元，2026 年至 2034 年的複合年成長率為 7.49%。

由於癌症和自體免疫疾病的日益普遍，全球免疫療法市場正經歷快速擴張。免疫療法利用人體自身的免疫系統對抗疾病，提供標靶且持久的治療效果。查核點抑制劑和單株抗體的核准不斷增加，顯著推動了市場成長。醫療保健支出的增加和診斷能力的提升，進一步促進了已開發市場和新興市場對免疫療法的採用。

關鍵成長要素包括生物製藥研究和個人化醫療方法的進步。製藥公司正大力投資臨床試驗，以拓展有療法的適應症。將免疫療法與化療或放射線治療結合的聯合療法也發展迅速。此外，支援性的法規結構和快速核准機制正在加速產品商業化進程。

隨著細胞療法和癌症疫苗的進步，未來前景十分光明。免疫療法藥物在感染疾病和慢性病領域的應用拓展將擴大市場範圍，而開發中國家醫療資源的改善也將進一步刺激需求。在科學突破的驅動下，免疫療法藥物市場可望保持強勁的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球免疫療法藥物市場：依藥物類型分類

• 市場分析、洞察與預測
• 單株抗體
• 免疫調節劑
• 細胞療法
• 其他（疫苗等）

第5章 全球免疫療法藥物市場：依治療領域分類

• 市場分析、洞察與預測
• 癌症
• 自體免疫疾病
• 感染疾病
• 其他

第6章 全球免疫療法藥物市場：依分銷管道分類

• 市場分析、洞察與預測
• 零售藥房
• 網路藥房
• 醫院藥房

第7章 全球免疫療法藥物市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 亞太其他地區
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Bristol Myers Squibb
  • Merck & Co. Inc
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • AstraZeneca
  • Pfizer Inc
  • Amgen Inc
  • Gilead Sciences
  • Regeneron Pharmaceuticals Inc
  • Eli Lilly And Company

The Immunotherapy Drugs Market size is expected to reach USD 345.58 Billion in 2034 from USD 180.40 Billion (2025) growing at a CAGR of 7.49% during 2026-2034.

The Global Immunotherapy Drugs market has experienced rapid expansion due to growing prevalence of cancer and autoimmune diseases. Immunotherapy harnesses the body's immune system to fight disease, offering targeted and durable treatment outcomes. Increasing approval of checkpoint inhibitors and monoclonal antibodies has significantly strengthened market growth. Rising healthcare expenditure and improved diagnostic capabilities further support widespread adoption across developed and emerging regions.

Key growth drivers include advancements in biologics research and personalized medicine approaches. Pharmaceutical companies are investing heavily in clinical trials to expand indications for existing therapies. Combination treatments integrating immunotherapy with chemotherapy or radiation are gaining momentum. Additionally, supportive regulatory frameworks and fast-track approvals accelerate product commercialization.

Future prospects remain highly promising as innovation in cell-based therapies and cancer vaccines advances. Expanding applications in infectious and chronic diseases will broaden the market scope. Improved accessibility in developing economies will further stimulate demand. The immunotherapy drugs market is expected to maintain strong long-term growth driven by scientific breakthroughs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Monoclonal Antibodies
• Immunomodulators
• Cell Therapy
• Others (Vaccines, etc.)

By Therapy Area

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

COMPANIES PROFILED

• Bristol Myers Squibb, Merck Co Inc, F HoffmannLa Roche AG, Novartis AG, AstraZeneca, Pfizer Inc, Amgen Inc, Gilead Sciences, Regeneron Pharmaceuticals Inc, Eli Lilly and Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others (Vaccines, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY THERAPY AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy Area
• 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Therapy Area
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Therapy Area
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Therapy Area
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Therapy Area
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Therapy Area
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Bristol Myers Squibb
  • 9.2.2 Merck & Co. Inc
  • 9.2.3 F. Hoffmann-La Roche AG
  • 9.2.4 Novartis AG
  • 9.2.5 AstraZeneca
  • 9.2.6 Pfizer Inc
  • 9.2.7 Amgen Inc
  • 9.2.8 Gilead Sciences
  • 9.2.9 Regeneron Pharmaceuticals Inc
  • 9.2.10 Eli Lilly And Company